Literature DB >> 24598801

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.

Kristian Vinter Juul1, Daniel G Bichet, Søren Nielsen, Jens Peter Nørgaard.   

Abstract

The arginine vasopressin (AVP) type 2 receptor (V2R) is unique among AVP receptor subtypes in signaling through cAMP. Its key function is in the kidneys, facilitating the urine concentrating mechanism through the AVP/V2 type receptor/aquaporin 2 system in the medullary and cortical collecting ducts. Recent clinical and research observations strongly support the existence of an extrarenal V2R. The clinical importance of the extrarenal V2R spans widely from stimulation of coagulation factor in the endothelium to as yet untested potential therapeutic targets. These include V2R-regulated membranous fluid turnover in the inner ear, V2R-regulated mitogensis and apoptosis in certain tumor tissues, and numerous other cell types where the physiological role of V2Rs still requires further research. Here, we review current evidence on the physiological and pathophysiological functions of renal and extrarenal V2Rs. These functions of V2R are important, not only in rare diseases with loss or gain of function of V2R but also in relation to the recent use of nonpeptide V2R antagonists to treat hyponatremia and possibly retard the growth of cysts and development of renal failure in autosomal dominant polycystic kidney disease. The main functions of V2R in principal cells of the collecting duct are water, salt, and urea transport by modifying the trafficking of aquaporin 2, epithelial Na(+) channels, and urea transporters and vasodilation and stimulation of coagulation factor properties, mainly seen with pharmacological doses of 1-desamino-8-D-AVP. The AVPR2 gene is located on the X chromosome, in a region with high probability of escape from inactivation; this may lead to phenotypic sex differences, with females expressing higher levels of transcript than males.

Entities:  

Keywords:  arginine vasopressin; arginine vasopressin V2 receptor; desmopressin; extrarenal vasopressin V2 receptor; vasopressin V2 receptor

Mesh:

Substances:

Year:  2014        PMID: 24598801     DOI: 10.1152/ajprenal.00604.2013

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  47 in total

Review 1.  Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus.

Authors:  B K Kishore; N G Carlson; C M Ecelbarger; D E Kohan; C E Müller; R D Nelson; J Peti-Peterdi; Y Zhang
Journal:  Acta Physiol (Oxf)       Date:  2015-05-04       Impact factor: 6.311

2.  Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V2 receptor-independent pathway.

Authors:  Yusuf Ali; Kaoru Dohi; Ryuji Okamoto; Kan Katayama; Masaaki Ito
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

Review 3.  Vasopressin receptor antagonists.

Authors:  Biff F Palmer
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

4.  Osmoregulation Performance and Kidney Transplant Outcome.

Authors:  Manal Mazloum; Jordan Jouffroy; François Brazier; Christophe Legendre; Antoine Neuraz; Nicolas Garcelon; Dominique Prié; Dany Anglicheau; Frank Bienaimé
Journal:  J Am Soc Nephrol       Date:  2019-06-19       Impact factor: 10.121

5.  Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Authors:  Olivier Devuyst; Arlene B Chapman; Ron T Gansevoort; Eiji Higashihara; Ronald D Perrone; Vicente E Torres; Jaime D Blais; Wen Zhou; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

6.  Novel activators of aquaporin 2 membrane expression for the treatment of nephrogenic diabetes insipidus: less is more. Focus on "High-throughput chemical screening identifies AG-490 as a stimulator of aquaporin 2 membrane expression and urine concentration".

Authors:  Jeff M Sands; Mitsi A Blount
Journal:  Am J Physiol Cell Physiol       Date:  2014-06-18       Impact factor: 4.249

Review 7.  Do we need to know more about the effects of hormones on lower urinary tract dysfunction? ICI-RS 2014.

Authors:  Ann T Hanna-Mitchell; Dudley Robinson; Linda Cardozo; Karel Everaert; Georgi V Petkov
Journal:  Neurourol Urodyn       Date:  2016-02       Impact factor: 2.696

8.  Chronic Hyponatremia Causes Neurologic and Psychologic Impairments.

Authors:  Haruki Fujisawa; Yoshihisa Sugimura; Hiroshi Takagi; Hiroyuki Mizoguchi; Hideyuki Takeuchi; Hisakazu Izumida; Kohtaro Nakashima; Hiroshi Ochiai; Seiji Takeuchi; Atsushi Kiyota; Kazuya Fukumoto; Shintaro Iwama; Yoshiko Takagishi; Yoshitaka Hayashi; Hiroshi Arima; Yukio Komatsu; Yoshiharu Murata; Yutaka Oiso
Journal:  J Am Soc Nephrol       Date:  2015-09-16       Impact factor: 10.121

9.  Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C.

Authors:  Michael L Ekaney; Clemens L Bockmeyer; Maik Sossdorf; Philipp A Reuken; Florian Conradi; Tobias Schuerholz; Markus F Blaess; Scott L Friedman; Wolfgang Lösche; Michael Bauer; Ralf A Claus
Journal:  Mol Med       Date:  2015-04-03       Impact factor: 6.354

10.  Activation of protein kinase Cα increases phosphorylation of the UT-A1 urea transporter at serine 494 in the inner medullary collecting duct.

Authors:  Mitsi A Blount; Penelope Cipriani; Sara K Redd; Ronald J Ordas; Lauren N Black; Diane L Gumina; Carol A Hoban; Janet D Klein; Jeff M Sands
Journal:  Am J Physiol Cell Physiol       Date:  2015-09-02       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.